Maqsood Amjad, MD
Hematology & Oncology · Robbinsville, NJNPI 1881631398
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Novocure Inc. accounts for 65.0% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2023 at $6,458 and has fallen 96.6% since, to $221 in 2025.
Across 80 payments — averaging $108.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$6K
- Bristol Myers Squibb$1K
- Daiichi Sankyo Inc.$154
- Karyopharm Therapeutics Inc.$150
- Exelixis Inc.$147
- E.r. Squibb & Sons, L.L.C.$141
- plus $1K from 32 others
Across 6 payments — averaging $3299.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$12K
- Janssen Research & Development, LLC$7K
What the payments were for
- Consulting fees$1,15513%
- Speaking & faculty fees$4,55052%
- Travel & lodging$7158%
- Food & beverage$2,01323%
- Education$2723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 7 | $5,657 |
| Bristol Myers Squibb | 3 | $1,189 |
| Daiichi Sankyo Inc. | 2 | $154 |
| Karyopharm Therapeutics Inc. | 3 | $150 |
| Exelixis Inc. | 2 | $147 |
| E.r. Squibb & Sons, L.L.C. | 4 | $141 |
| Incyte Corporation | 4 | $114 |
| Blueprint Medicines Corporation | 2 | $113 |
| Seagen Inc. | 1 | $100 |
| Novartis | 4 | $77 |
| Astellas Pharma US Inc | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $68 |
| Pfizer | 3 | $60 |
| AstraZeneca | 4 | $59 |
| GSK | 3 | $54 |
| AbbVie | 3 | $54 |
| Gilead | 3 | $39 |
| Merck | 2 | $36 |
| Johnson & Johnson | 2 | $36 |
| Eisai Inc. | 2 | $35 |
| Emmaus Medical, Inc. | 1 | $29 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Amgen | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Spectrum Pharmaceuticals Inc. | 1 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Array Biopharma Inc | 1 | $18 |
| Telix Pharmaceuticals | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
| Sobi, Inc | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Beigene USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,704 in reported general payments places this provider in the 70th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 53 | $789,681 |
| RevlimidLenalidomide | 33 | $665,292 |
| JakafiRuxolitinib Phosphate | 23 | $403,632 |
| PomalystPomalidomide | 17 | $384,608 |
| NplateRomiplostim | 18 | $279,738 |
| XtandiEnzalutamide | 14 | $230,814 |
| AranespDarbepoetin Alfa In Polysorbat | 85 | $179,931 |
| EliquisApixaban | 89 | $106,028 |
| NeulastaPegfilgrastim | 14 | $105,358 |
| ProcritEpoetin Alfa | 56 | $104,526 |
| XgevaDenosumab | 15 | $69,449 |
| Lupron DepotLeuprolide Acetate | 11 | $65,089 |
| MvasiBevacizumab-Awwb | 17 | $49,098 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $41,719 |
| XareltoRivaroxaban | 11 | $16,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $59 | $789,68153 claims |
| AmgenNplate, Aranesp, Neulasta, Xgeva, Mvasi | $24 | $683,574149 claims |
| Bristol Myers SquibbRevlimid | $1,189 | $665,29233 claims |
| Incyte CorporationJakafi | $114 | $403,63223 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $141 | $384,60817 claims |
| Astellas Pharma US IncXtandi | $76 | $230,81414 claims |
| Johnson & JohnsonProcrit, Xarelto | $36 | $121,48767 claims |
| PfizerEliquis | $60 | $106,02889 claims |
| AbbVieLupron Depot, Creon | $54 | $81,36222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Robbinsville
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
- Anthony BottiLivingston$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.